Losartan Potassium
Product Images NDC 68151-0182

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68151-0182). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (92296151 E507 41b4 A040 C01b87ecb982 01)

Figure 1 (92296151 E507 41b4 A040 C01b87ecb982 01)
Chemical structure of Losartan Potassium, showing its molecular composition and arrangement including the potassium ion (K+).*
FDA Label Image

Figure 2 (92296151 E507 41b4 A040 C01b87ecb982 02)

Figure 2 (92296151 E507 41b4 A040 C01b87ecb982 02)
A line graph comparing the percentage of patients reaching the primary endpoint over time in months between atenolol (dotted line) and Losartan Potassium Tablets (solid line). The x-axis shows study duration from 0 to 66 months, and the y-axis shows percentage of patients up to 16%. The graph includes an annotation indicating a 13% adjusted risk reduction with a p-value of 0.021 for Losartan Potassium Tablets.*
FDA Label Image

Figure 3 (92296151 E507 41b4 A040 C01b87ecb982 03)

Figure 3 (92296151 E507 41b4 A040 C01b87ecb982 03)
A line graph comparing the percentage of patients with fatal or non-fatal stroke over a study period of up to 60 months. It shows two lines representing Atenolol (dotted) and Losartan Potassium Tablets (solid), indicating a difference in stroke risk over time. The graph includes an annotation of an adjusted risk reduction of 25% with a significance level (p=0.001).*
FDA Label Image

Figure 4 (92296151 E507 41b4 A040 C01b87ecb982 04)

Figure 4 (92296151 E507 41b4 A040 C01b87ecb982 04)
A forest plot comparing hazard ratios with 95% confidence intervals for overall and stroke (fatal/non-fatal) outcomes between Losartan Potassium Tablets and Amlodipine, stratified by patient demographics and clinical characteristics such as age, gender, race, ISH, diabetes, and history of cardiovascular disease.*
FDA Label Image

Figure 5 (92296151 E507 41b4 A040 C01b87ecb982 05)

Figure 5 (92296151 E507 41b4 A040 C01b87ecb982 05)
A line graph comparing the percentage of patients with an event over 48 months for Losartan Potassium Tablets versus placebo. The graph shows time in months on the x-axis and percentage of patients with event on the y-axis, indicating a 16.1% risk reduction with Losartan Potassium Tablets compared to placebo.*
FDA Label Image

Figure 6 (92296151 E507 41b4 A040 C01b87ecb982 06)

Figure 6 (92296151 E507 41b4 A040 C01b87ecb982 06)
FDA Label Image

Figure 6 (92296151 E507 41b4 A040 C01b87ecb982 07)

Figure 6 (92296151 E507 41b4 A040 C01b87ecb982 07)
FDA Label Image

Label Image (Lbl681510182)

Label Image (Lbl681510182)
Losartan Potassium 25 mg tablets label showing the manufacturer as Torrent. The label includes lot number B0493003, expiration date 11/14, and product code PDM 0182. It is marked for prescription use only (RX ONLY) and includes barcodes with the product NDC 68151-0182.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.